Chiral NHC/Cu(I)-Catalyzed Asymmetric Hydroboration of Aldimines: Enantioselective Synthesis of α-Amido Boronic Esters

Shu-Sheng Zhang; Yi-Shuang Zhao; Ping Tian; Guo-Qiang Lin

doi:10.1055/s-0032-1318145

Synlett, Inhaltsverzeichnis

Synlett 2013; 24(4): 437-442
DOI: 10.1055/s-0032-1318145

letter

Chiral NHC/Cu(I)-Catalyzed Asymmetric Hydroboration of Aldimines: Enantioselective Synthesis of α-Amido Boronic Esters

Shu-Sheng Zhang

Key Laboratory of Synthetic Chemistry of Natural Substances, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 345 Lingling Road, Shanghai 200032, P. R. of China Fax: +86(21)64166263 eMail: tianping@sioc.ac.cn eMail: lingq@sioc.ac.cn

,

Yi-Shuang Zhao

Key Laboratory of Synthetic Chemistry of Natural Substances, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 345 Lingling Road, Shanghai 200032, P. R. of China Fax: +86(21)64166263 eMail: tianping@sioc.ac.cn eMail: lingq@sioc.ac.cn

,

Ping Tian*

Key Laboratory of Synthetic Chemistry of Natural Substances, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 345 Lingling Road, Shanghai 200032, P. R. of China Fax: +86(21)64166263 eMail: tianping@sioc.ac.cn eMail: lingq@sioc.ac.cn

,

Guo-Qiang Lin*

Key Laboratory of Synthetic Chemistry of Natural Substances, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 345 Lingling Road, Shanghai 200032, P. R. of China Fax: +86(21)64166263 eMail: tianping@sioc.ac.cn eMail: lingq@sioc.ac.cn

› Institutsangaben

Abstract

Alle Artikel dieser Rubrik

Abstract

Non-C ₂-symmetric (N-alkyl, N-aryl)-hybrid chiral NHC/Cu(I) complex catalyzed asymmetric hydroboration of N-benzoyl aldimines has been developed. The reaction proceeded smoothly at room temperature, giving α-amido boronic esters in excellent yields (up to 94%) and good enantioselectivities (up to 86% ee).

Key words

chiral NHCs - copper - asymmetric hydroboration - aldimines - α-amido boronic esters

Volltext

Referenzen

References

For recent reviews on peptide α-amino boronic acids as protease inhibitors, see:

1a Huber EM, Groll M. Angew. Chem. Int. Ed. 2012; 51: 8708
1b Smoum R, Rubinstein A, Dembitsky VM, Srebnik M. Chem. Rev. 2012; 112: 4156
1c Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, Harousseau J.-L. Blood 2012; 120: 947
1d Baker SJ, Ding CZ, Akama T, Zhang Y.-K, Hernandez V, Xia Y. Future Med. Chem. 2009; 1: 1275
1e Yang W.-Q, Gao X.-M, Wang B.-H. Biological and Medicinal Applications of Boronic Acids. In Boronic Acids . Hall DG. Wiley-VCH; Weinheim, Germany: 2005. Chap. 13 48

2 See: http://www.velcade.com.
3 Kupperman E, Lee EC, Cao Y, Bannerman B, Fitzgerald M, Berger A, Yu J, Yang Y, Hales P, Bruzzese F, Liu J, Blank J, Garcia K, Tsu C, Dick L, Fleming P, Yu L, Manfredi M, Rolfe M, Bolen J. Cancer Res. 2010; 70: 1970
4 Monami M, Lamanna C, Desideri CM, Mannucci E. Adv. Ther. 2012; 29: 14
5 Piva R, Ruggeri B, Williams M, Costa G, Tamagno I, Ferrero D, Giai V, Coscia M, Peola S, Massaia M, Pezzoni G, Allievi C, Pescalli N, Cassin M, di Giovine S, Nicoli P, de Feudis P, Strepponi I, Roato I, Ferracini R, Bussolati B, Camussi G, Jones-Bolin S, Hunter K, Zhao H, Neri A, Palumbo A, Berkers C, Ovaa H, Bernareggi A, Inghirami G. Blood 2008; 111: 2765

6a Matteson DS, Sadhu KM. J. Am. Chem. Soc. 1981; 103: 5241
6b Matteson DS. (α-Haloalkyl)boronic Esters in Asymmetric Synthesis. In Boronic Acids . Hall DG. Wiley-VCH; Weinheim, Germany: 2005. Chap. 8 305
6c Matteson DS, Beedle EC. Tetrahedron Lett. 1987; 28: 4499
6d Jadhav PK, Man H. J. Org. Chem. 1996; 61: 7951

7 Gazić SmilovićI, Casas-Arcé E, Roseblade SJ, Nettekoven U, Zanotti-Gerosa A, Kovačevič M, Časar Z. Angew. Chem. Int. Ed. 2012; 51: 1014
8 Beenen MA, An C.-H, Ellman JA. J. Am. Chem. Soc. 2008; 130: 6910
9 Ellman JA, Owens TD, Tang TP. Acc. Chem. Res. 2002; 35: 984
10 Solé C, Gulyás H, Fernández E. Chem. Commun. 2012; 48: 3769

For an important synthetic use of enantioenriched α-(acylamino)benzylboronic esters in Suzuki–Miyaura coupling, see:

11a Ohmura T, Awano T, Suginome M. J. Am. Chem. Soc. 2010; 132: 13191
11b Awano T, Ohmura T, Suginome M. J. Am. Chem. Soc. 2011; 133: 20738

12 O’Brien JM, Lee K.-S, Hoveyda AH. J. Am. Chem. Soc. 2010; 132: 10630

13a Lee Y, Hoveyda AH. J. Am. Chem. Soc. 2009; 131: 3160
13b Corberán R, Mszar NW, Hoveyda AH. Angew. Chem. Int. Ed. 2011; 50: 7079

14 Lee Y, Jang H, Hoveyda AH. J. Am. Chem. Soc. 2009; 131: 18234
15 For a recent review about synthetic routes to N-heterocyclic carbene precursors, see: Benhamou L, Chardon E, Lavigne G, Bellemin-Laponnaz S, César V. Chem. Rev. 2011; 111: 2705
16 See Supporting Information for the detailed procedure of the preparation of chiral imidazolinium salts NHC₂ –NHC₇ . Analytical data of some typical imidazolinium salts: NHC₅ : [α]_D ²³ +318.7 (c = 1.37, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ = 9.86 (s, 1 H), 8.17 (d, J = 7.6 Hz, 1 H), 7.17–7.56 (m, 16 H), 6.97 (d, J = 7.6 Hz, 2 H), 4.99 (d, J = 10.0 Hz, 1 H), 4.39 (d, J = 10.0 Hz, 1 H), 3.88 (s, 3 H). ¹³C NMR (100 MHz, CDCl₃): δ = 158.04, 137.94, 137.77, 134.10, 133.95, 132.02, 130.82, 129.83, 129.64, 129.51, 129.42, 129.16, 129.10, 129.04, 128.58, 128.28, 127.48, 75.83, 74.60, 35.20. MS (ESI): m/z = 389.2 [C₂₈H₂₅IN₂ – I]⁺. HRMS: m/z [M]⁺ calcd for C₂₈H₂₅N₂: 389.20177; found: 389.20140. NHC₆ : [α]_D ²³ +454.0 (c = 0.845, CHCl₃). ¹H NMR (400 MHz, CDCl₃): δ = 8.67 (s, 1 H), 7.54 (m, 3 H), 7.32–7.42 (m, 10 H), 7.12–7.17 (m, 3 H), 6.81 (d, J = 7.6 Hz, 2 H), 5.14 (d, J = 8.8 Hz, 1 H), 3.88 (m, 1 H), 1.69–1.94 (m, 6 H), 1.54 (m, 1 H), 1.32–1.42 (m, 1 H), 1.09–1.27 (m, 3 H), 1.19 (s, 9 H). ¹³C NMR (100 MHz, CDCl₃): δ = 155.83, 152.92, 138.12, 135.44, 135.39, 134.82, 131.53, 130.44, 129.94, 129.58, 129.44, 129.22, 129.18, 128.21, 127.92, 127.23, 126.46, 75.96, 72.09, 57.94, 34.65, 31.44, 30.75, 25.08, 24.90, 24.44. MS (ESI): m/z = 513.3 [M – BF₄]⁺. HRMS: m/z [M – BF₄]⁺ calcd for C₃₇H₄₁N₂ ⁺: 513.32697; found: 513.32435.
17 Park JK, Lackey HH, Rexford MD, Kovnir K, Shatruk M, McQuade DT. Org. Lett. 2010; 12: 5008

For pharmaceutically interesting α-amido boronic acids, see:

18a Contreras-Martel C, Amoroso A, Woon EC. Y, Zervosen A, Inglis S, Martins A, Verlaine O, Rydzik AM, Job V, Luxen A, Joris B, Schofield CJ, Dessen A. ACS Chem. Biol. 2011; 6: 943
18b Woon EC. Y, Zervosen A, Sauvage E, Simmons KJ, Zivec M, Inglis SR, Fishwick CW. G, Gobec S, Charlier P, Luxen A, Schofield CJ. ACS Med. Chem. Lett. 2011; 2: 219
18c Morandi F, Caselli E, Morandi S, Focia PJ, Blazquez J, Shoichet BK, Prati F. J. Am. Chem. Soc. 2003; 125: 685

19 General Procedure for NHC₆/CuCl-Catalyzed Asymmetric Hydroboration of Aldimines: In the glovebox, an oven-dried Schlenk tube equipped with a stir bar, imidazolinium tetrafluoroborate salt NHC₆ (36 mg, 0.06 mmol), t-BuONa (12 mg, 0.12 mmol), and CuCl (5 mg, 0.05 mmol) were placed and anhyd toluene (2.0 mL) was added. After the solution was allowed to stir for 2 h at 25 °C under an anhyd N₂ atmosphere, it was filtered through a syringe filter (rinsed with 1.0 mL of toluene) and placed in a separate oven-dried Schlenk tube. The resulting solution was charged with B₂(Pin)₂ (2, 152 mg, 0.6 mmol) and N-benzoyl aldimine (0.5 mmol). The Schlenk tube was removed from the glovebox and the mixture was allowed to stir for 12 h at r.t. After the reaction completed, the mixture was filtered through a short plug of Celite and rinsed with EtOAc, and the solution was concentrated under reduced pressure. The products²⁰ were isolated by rapid silica gel chromatography on deactivated silica gel (containing 35% H₂O) using PE–EtOAc (2:1) mixtures and were visualized with CAM (Ceric Ammonium Molybdate) stain.
20 Analytical data of some typical compounds: 3a: [α]_D ²⁸ –22.1 (c = 0.95, CHCl₃) for 63% ee. ¹H NMR (400 MHz, CDCl₃): δ = 3.67 (s, 3 H), 3.99 (s, 3 H), 4.58 (q, J = 10.4 Hz, 2 H), 6.54 (s, 4 H), 7.13 (d, J = 8.8 Hz, 1 H), 7.32–7.52 (m, 5 H), 7.89–7.94 (m, 3 H), 9.36 (s, 1 H). HPLC: Chiralcel AS-H Column (250 mm); detected at λ = 220 nm; n-hexane–i-propanol = 95:5; flow = 0.6 mL/min; t _R = 8.6 min (minor), t _R = 11.5 min (major). 3b: [α]_D ²⁸ –1.24 (c = 0.56, DMSO) for 74% ee; mp 142–144 °C. ¹H NMR (400 MHz, DMSO-d ₆): δ = 10.89 (s, 1 H), 8.07 (d, J = 7.6 Hz, 2 H), 7.73(t, J = 7.4 Hz, 1 H), 7.62 (t, J = 7.6 Hz, 2 H), 7.03–7.13(m, 4 H), 3.77 (s, 1 H), 1.03 (s, 6 H), 0.93 (s, 6 H). ¹³C NMR (100 MHz, DMSO-d ₆): δ = 171.53, 160.78 (d, J = 954.0 Hz), 138.81 (d, J = 12.0 Hz), 134.51, 129.59, 128.86, 128.57 (d, J = 32.4 Hz), 126.69, 114.72 (d, J = 84.8 Hz), 79.80, 25.65, 25.39. MS (ESI): m/z = 378.2 [M + H]⁺. HRMS: m/z [M + Na]⁺ calcd for C₂₀H₂₃BFNO₃: 377.16835; found: 377.16957. HPLC: Chiralcel AS-H Column (250 mm); detected at λ = 220 nm; n-hexane–i-propanol = 95:5; flow = 0.6 mL/min; t _R = 9.1 min (minor), t _R = 11.2 min (major). 3h: [α]_D ²³ –29.7 (c = 0.21, DMSO) for 80% ee; mp 156–157 °C. ¹H NMR (400 MHz, DMSO-d ₆): δ = 9.84 (s, 1 H), 7.99 (d, J = 7.6 Hz, 2 H), 7.68 (t, J = 7.4 Hz, 1 H), 7.58 (t, J = 7.8 Hz, 2 H), 2.38 (m, 4 H), 1.50–1.83 (m, 7 H), 0.99–1.32 (m, 4 H), 0.913 (s, 12 H). ¹³C NMR (100 MHz, DMSO-d ₆): δ = 170.39, 133.66, 129.27, 128.60, 79.88, 39.69, 31.21, 29.49, 26.73, 26.68, 26.66, 26.02, 25.83. MS (ESI): m/z = 366.3 [M + H]⁺. HRMS: m/z [M + Na]⁺ calcd for C₂₀H₃₀BNO₃: 365.22528; found: 365.22450. HPLC: Chiralpak AD-H Column (250 mm); detected at λ = 220 nm; n-hexane–i-propanol = 95:5; flow = 0.6 mL/min; t _R = 5.4 min (minor), t _R = 6.9 min (major). 3i: [α]²³ _D –48.66 (c = 0.385, DMSO) for 84% ee; mp 144–146 °C. ¹H NMR (400 MHz, DMSO-d ₆): δ = 10.00 (s, 1 H), 7.97 (d, J = 7.2 Hz, 2 H), 7.67 (t, J = 7.2 Hz, 1 H), 7.56 (t, J = 7.6 Hz, 2 H), 2.57 (m, 1 H), 1.83 (m, 1 H), 1.31 (m, 2 H), 1.11 (s, 12 H), 0.90 (d, J = 6.4 Hz, 6 H). ¹³C NMR (100 MHz, DMSO-d ₆): δ = 170.19, 133.76, 129.28, 128.61, 127.89, 79.89, 44.36, 25.86, 25.73, 25.49, 23.91, 22.57. MS (ESI): m/z = 340.2 [M + Na]⁺. HRMS: m/z [M + Na]⁺ calcd for C₁₈H₂₈BNO₃: 339.20963; found: 339.20870. HPLC: Chiralpak AD-H Column (250 mm); detected at λ = 220 nm; n-hexane–i-propanol = 95:5; flow = 0.6 mL/min; t _R = 7.8 min (minor), t _R = 8.9 min (major).

Zusatzmaterial

Supporting Information